SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES AMONG PATIENTS OF DIFFERENT AGE GROUPS WITH A HISTORY OF MYOCARDIAL INFARCTION BY THE EXAMPLE OF OUTPATIENT CARDIOLOGY INSTITUTION
Abstract
Aim. To study secondary prevention of cardiovascular diseases among patients of different age groups with a history of myocardial infarction by the example of outpatient cardiology institution.
Material and methods. Retrospective pharmacoepidemiological study was conducted by analyzing the medical records of 825 patients with a history of myocardial infarction, who visited the outpatient cardiology institution for the first time in 2011. Patients were divided into two groups according to their age: younger than 60 years (n=308), and 60 years and older (n=517).
Results. The population of elderly patients was more severe: significantly more often patients had disability and comorbidities. The prevalence of the main modifiable risk factors could not be assessed fully due to the lack of information in patients’ medical records. Elderly patients were significantly less likely to receive β-blockers (80.3%) and statins (63.8%). No significant differences were found in daily doses of the main prescribed preventive drugs between two groups.
Conclusion. Secondary prevention of cardiovascular diseases among patients of different age groups could not be considered proper, as there is low level of attention to the modifiable risk factors and recommendation on their correction. A tendency to under-prescription of angiotensin converting enzyme inhibitors was revealed, as well as significantly lower number of recommendations for taking statins and β-adrenoblockers in the group of elderly patients.
About the Authors
S. B. Fitilev
Peoples’ Friendship University of Russia
Russian Federation
Sergey B. Fitilev – MD, PhD, Professor, Chair of General and Clinical Pharmacology, Medical Institute
Russian Federation
Sergey B. Fitilev – MD, PhD, Professor, Chair of General and Clinical Pharmacology, Medical Institute
D. A. Dimitrova
Peoples’ Friendship University of Russia
Russian Federation
Darya A. Dimitrova – PharmD, Graduate Student, Chair of General and Clinical Pharmacology, Medical Institute
Russian Federation
Darya A. Dimitrova – PharmD, Graduate Student, Chair of General and Clinical Pharmacology, Medical Institute
I. I. Shkrebneva
Peoples’ Friendship University of Russia
Russian Federation
Irina I. Shkrebneva – MD, PhD, Associate Professor, Chair of General and Clinical Pharmacology, Medical Institute
Russian Federation
Irina I. Shkrebneva – MD, PhD, Associate Professor, Chair of General and Clinical Pharmacology, Medical Institute
A. V. Vozzhaev
Peoples’ Friendship University of Russia
Russian Federation
Alexander V. Vozzhaev – PhD (Biology), Associate Professor, Chair of General and Clinical Pharmacology, Medical Institute
Russian Federation
Alexander V. Vozzhaev – PhD (Biology), Associate Professor, Chair of General and Clinical Pharmacology, Medical Institute
References
1. Ushkalova E.A., Tkacheva O.N., Runikhina O.N., et al. Features of pharmacotherapy in the elderly patients. Introduction to the problem. Ration Pharmacother Cardiol. 2016;12(1):94-100. (In Russ.) [Ушкалова Е.А., Ткачева О.Н., Рунихина Н.К. и др. Особенности фармакотерапии у пожилых пациентов. Введение в проблему. Рациональная Фармакотерапия в Кардиологии. 2016;12(1):94-100].
2. Boden W.E., Maron D.J. Reducing Post-Myocardial Infarction in the Elderly. The Power and Promise of Secondary Prevention. JACC. 2008;51(13):1255-7.
3. Petrov V.I. Geriatric pharmacology. Vestnik VolGMU. 2011;1(37):3-7. (In Russ.) [Петров В. И. Гериатрическая фармакология. Вестник ВолгГМУ. 2011;1(37):3-7].
4. UNFPA and HelpAge International. Ageing in the Twenty-First Century: A Celebration and A Challenge. New York, NY: UNFPA and HelpAge International: 2012.
5. Nakamura S., Adachi H., Enomoto M., et al. Trends in coronary risk factors and electrocardiogram findings from 1977 to 2009 with 10-year mortality in Japanese elderly males - The Tanushimaru Study. J Cardiol. 2017 Jan 18. pii: S0914-5087(16)30345-8.
6. Lazarenko A. State-of-the-art of cardiovascular prophylaxis in Europe and Ukraine: results from EUROASPIRE IV trial. Zdorovie Ukraini. 2014;16-17. (In Russ.) [Лазаренко A. Современное состояние кардиоваскулярной профилактики в Европе и Украине: результаты исследования EUROASPIRE IV. Здоровье Украины 2014; 16-17].
7. Selivestrova D.V., Evsina O.V. Miocardial infarction in young patients: risk factors, disease course, clinical picture, care during hospitalization. Nauka molodih - Eruditio Juvenium. 2013;4:104-9. (In Russ.) [Селиверстова Д.В., Евсина О.В. Инфаркт миокарда у пациентов молодого возраста: факторы риска, течение, клиника, ведение на госпитальном этапе. Наука молодых - Eruditio Juvenium. 2013;4:104-9].
8. Alkhawam H., Sogomonian R., El-Hunjul M., et al. Risk factors for coronary artery disease and acute coronary syndrome in patients ≤40 years old. Future Cardiology. 2016;12(5):545-52.
9. Alexander K.P., Roe M.T., Chen A.Y., et al. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. JACC. 2005;46:1479-87.
10. Avezum A., Makdisse M., Spencer F., et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2005;149:67-73.
11. Soedamah-Muthu S. S., Geleijnse J.M., Giltay E.J., et al. Levels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006. Neth Heart J. 2012;20(3):102-9.
12. Levy A.R., Tamblyn R.M., Mcleod P.J., et al. The Effect of Physicians’ Training on Prescribing for Secondary Prevention of Myocardial infarction in the Elderly. Ann Epidemiol. 2002;12:86-9.
13. Pilote L., Abrahamowicz M., Rodrigues E. et al. Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect? Ann Intern Med. 2004;141:102-12.
14. Rockwood K., Kirkland S., Hogan D.B., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59(2):223-7.
15. Barsukov A.V., Talantseva M.S., Sveklina T.S., et al. Hypolipidemic therapy in eldery patients. In focus - statins and prognosis. Arterialnaya Gipertenzia. 2011;17(5):415-24. (In Russ.) [Барсуков А.В., Таланцева М.С., Свёклина Т.С. и др. Гиполипидемическая терапия у пожилых пациентов. В фокусе - статины и прогноз. Артериальная Гипертензия. 2011;17(5):415-24].
16. Ushkalova E.A., Tkacheva O.N., Runikhina O.N., et al. Efficacy and safety of lipid-lowering drugs in primary and secondary prevention of cardiovascular diseases in the elderly. Ration Pharmacother Cardiol. 2016;12(3):351-8. (In Russ.) [Ушкалова Е.А., Ткачева О.Н., Рунихина Н.К. и др. Эффективность и безопасность гиполипидемических препаратов в качестве средств первичной и вторичной профилактики сердечно-сосудистых заболеваний у лиц пожилого возраста. Рациональная Фармакотерапия в Кардиологии. 2016;12(3):351-8].
Review
For citations:
Fitilev S.B., Dimitrova D.A., Shkrebneva I.I., Vozzhaev A.V. SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES AMONG PATIENTS OF DIFFERENT AGE GROUPS WITH A HISTORY OF MYOCARDIAL INFARCTION BY THE EXAMPLE OF OUTPATIENT CARDIOLOGY INSTITUTION. Rational Pharmacotherapy in Cardiology. 2017;13(3):317-322. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-3-317-322
Views: 607
Email this article 